NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»23/04/2010 [Company watch]
NeoStem and ImmuneRegen to Collaborate on Stem Cells

NeoStem and ImmuneRegen BioSciences have announced a collaborative research agreement, which focuses on the development of an advanced, adult human stem cell product.

 

NeoStem and ImmuneRegen BioSciences have announced a collaborative research agreement, which focuses on the development of an advanced, adult human stem cell product.

Under the agreement, NeoStem will investigate the effects of Homspera, ImmuneRegen\'s lead drug candidate, which, when used with NeoStem\'s VSEL(TM) technology, has been shown to enhance stem cell activity.

ImmuneRegen\'s Homspera has previously been shown to affect the differentiation of human adult stem cells, particularly into hematopoietic stem cells that are capable of becoming blood cells.

Under the collaboration, NeoStem has the right to execute an option agreement to negotiate an exclusive licence to resulting technology.

NeoStem is pursuing the research and development of adult stem cell therapies, both in the US and China, from small embryonic-like stem cells, which represents a significant step towards overcoming the ethical limitations in the development of stem cell therapies.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.